Actively Recruiting
Comparing Two Oral Forms of Olomorasib in Healthy Adults to Study Drug Absorption and Side Effects
Led by Eli Lilly and Company · Updated on 2026-09-22
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates how olomorasib, a drug, enters the bloodstream when taken in two different oral forms. The study compares the amount and speed of absorption to understand the drugs behavior in healthy adult volunteers aged 18 to 55. The research is conducted as a Phase 1, open-label, randomized study sponsored by Eli Lilly and Company. Participants will receive olomorasib in two ways as an intact oral capsule and as a water dispersion. The study uses a crossover design, meaning each participant will receive both forms of the drug in separate periods. The administration is oral, and the study includes one continuous stay in the Clinical Research Unit lasting 7 nights. Each participant will be involved in the study for about 6 weeks, including the 7-night stay in the unit. During this time, researchers will monitor the concentration of olomorasib in the blood from Day 1 to Day 7 to assess the pharmacokinetics, especially the maximum concentration Cmax. The study will also check for any side effects or reactions to the drug. This close monitoring helps ensure participant safety and provides detailed information about the drugs absorption.
CONDITIONS
Brief Title
A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here